Ischemic Heart Disease Clinical Trial
Official title:
Myocardial Perfusion Imaging by 15O-H2O PET/CT: Reference Values and Prognostic Value
The trial will include 5000 patients with evident or suspected ischemic heart disease refered to Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, for perfusion imaging by 15O-H2O PET/CT scan of the heart during rest and stress. The patients will undergo the clinical scan as normal. Data from the scans will be used to determine reference values of the examination. Follow up will be done for up to 10 years in regards to major cardiovascular events in order to determine the prognostic value of the scan.
Status | Recruiting |
Enrollment | 5000 |
Est. completion date | August 1, 2036 |
Est. primary completion date | August 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Known or suspected ischemic heart disease referred for a clinical H2O-PET at Department of Nuclear Medicine and PET Centre, Aarhus University Hospital Exclusion Criteria: - Claustrophobia, severe asthma, younger than 18 years |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus | Aarhus N |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prognostic value within 10 years | Number of participants who experience a major adverse cardiac event within 10 years of follow-up. | 10 years | |
Secondary | Myocardial blood flow | The myocardial blood flow of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Coronary flow reserve | The coronary flow reserve of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Pulmonary transit time | The pulmonary transit time of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Left ventricular end-systolic volume | The left ventricular end-systolic volume of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Left ventricular end-diastolic volume | The left ventricular end-diastolic volume of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Right ventricular end-systolic volume | The right ventricular end-systolic volume of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Right ventricular end-diastolic volume | The right ventricular end-diastolic volume of participants assessed by 15O-H2O PET/CT | 5 Years | |
Secondary | Immediate coronary angiography followup | Number of participants who undergo coronary angiography within 3 months after primary 15O-H2O PET/CT | 5 years | |
Secondary | Immediate percutaneous coronary intervention (PCI) followup | Number of participants who undergo percutaneous coronary intervention within 3 months after primary 15O-H2O PET/CT | 5 years | |
Secondary | Immediate coronary artery bypass graft (CABG) followup | Number of participants who undergo coronary artery bypass graft within 3 months after primary 15O-H2O PET/CT | 5 years | |
Secondary | Prognostic value within 5 years | Number of participants who experience a major adverse cardiac event within 5 years of follow-up. | 5 years | |
Secondary | Prognostic value within 2 years | Number of participants who experience a major adverse cardiac event within 2 years of follow-up. | 2 years | |
Secondary | Prognostic value within 1 years | Number of participants who experience a major adverse cardiac event within 1 years of follow-up. | 1 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |